March 2026 Patent Highlights

Key Takeaways

• 38 first‑time small‑molecule drugs approved by EMA, NMPA, and PMDA in 2025
• Oncology leads approvals, followed by infectious‑disease agents targeting HCV, flu, COVID‑19
• HPK1 inhibitor optimized for potency, selectivity, CYP2D6 safety, and cardiovascular risk
• AACR San Diego 2026 unveiled 11 novel oncology agents across modalities
• Zalsupindole, a non‑hallucinogenic neuroplastogen, enters clinical trials for mental health

Pulse Analysis

Global regulators are moving faster than ever. In 2025, Europe’s EMA, China’s NMPA and Japan’s PMDA granted 38 first‑time approvals for small‑molecule drugs, with oncology accounting for the majority and infectious‑disease agents targeting HCV, influenza and COVID‑19 filling the second tier. This surge reflects a maturing pipeline outside the United States and highlights the importance of cross‑border regulatory intelligence for companies seeking market entry and investors tracking diversification of revenue streams.

At the same time, advances in protein‑structure determination—driven by cryo‑EM, X‑ray crystallography and AI‑based modeling—are reshaping target discovery. The HPK1 inhibitor case study illustrates how structural insights, combined with property‑focused medicinal chemistry, can resolve metabolic liabilities, achieve kinase selectivity via the unique GGG motif, and mitigate CYP2D6 polymorphism and cardiovascular risks. Such integrated approaches are becoming a blueprint for rapid progression from hit to clinical candidate in immuno‑oncology.

The AACR San Diego 2026 meeting and emerging neuroplastogen research further expand the therapeutic horizon. Eleven novel oncology agents, spanning small molecules to biologics, were disclosed, indicating a robust pipeline that could soon translate into new standards of care. Concurrently, the first clinical candidate in the neuroplastogen class, zalsupindole, offers a non‑hallucinogenic route to treat mental‑health disorders, addressing a high‑unmet‑need market. Together, these trends underscore a diversification of drug modalities and a heightened emphasis on safety, efficacy, and rapid regulatory pathways.